



**MaxCyte, Inc.**  
("MaxCyte" or the "Company")

### **Grant of Options, RSUs and PSUs and PDMR Dealing**

**Rockville, Maryland - 24 March 2025:** MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, announces that on 14 March 2025, a grant of 347,500 stock options in respect to common stock of the Company, and a target grant of 347,500 performance stock units ("PSUs") were granted to Maher Masoud, President, Chief Executive Officer and Director of the Company, and 150,000 options in respect of common stock in the Company, 37,500 restricted stock units ("RSUs") and a target grant of 37,500 PSUs were granted to Douglas Swirsky, Chief Financial Officer of the Company.

#### **Details of the stock options**

The options granted to Messrs. Masoud and Swirsky vest as to 25% of the total grant on the first anniversary of the date of grant, and the remaining 75% vest in 36 equal monthly instalments thereafter.

The options granted to Messrs. Masoud and Swirsky have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price of 3.29, being equal to the closing price of MaxCyte's common stock on Nasdaq on 14 March 2025.

#### **Details of the RSUs**

Each RSU represents the contingent right to receive one share of common stock in the Company. The RSUs granted to Mr. Swirsky vest as to 25% on each of the first, second, third and fourth anniversary of the date of grant. No exercise price is payable on vesting or settlement of the RSUs.

#### **Details of the PSUs**

Each PSU represents the contingent right to receive one share of common stock in the Company upon the achievement of specified performance metrics. The PSU grants made to Messrs. Masoud and Swirsky on 14 March 2025 represent a number of shares of common stock to be earned if the target level of performance is achieved. The performance period continues through 31 December 2027, after which time the level of performance achievement will be determined by the Board of Directors or an authorized committee thereof. The actual number of shares of common stock underlying the PSUs to be earned will be between 0% and 125% of the target number of PSUs, depending on the level of achievement of such performance metrics. No exercise price is payable on the vesting or settlement of the PSUs.

The information in the tables below is provided in accordance with the requirements of the UK Market Abuse Regulation.

#### **About MaxCyte**

MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® technology, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx®, STx®, GTx® and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. Learn more at [maxcyte.com](https://maxcyte.com) and follow us on [Twitter](https://twitter.com/MaxCyte) and [LinkedIn](https://www.linkedin.com/company/maxcyte).

#### **MaxCyte Contacts:**

**US IR Adviser**  
**Gilmartin Group**  
David Deuchler, CFA

+1 415-937-5400  
[ir@maxcyte.com](mailto:ir@maxcyte.com)

**Nominated Adviser and Joint  
Corporate Broker**  
Panmure Liberum  
Emma Earl / Freddy Crossley  
Corporate Broking  
Rupert Dearden

+44 (0)20 7886 2500

**UK IR Adviser**  
**ICR Healthcare**  
Mary-Jane Elliott  
Chris Welsh

+44 (0)203 709 5700  
[maxcyte@icrhealthcare.com](mailto:maxcyte@icrhealthcare.com)

## About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 25 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at [maxcyte.com](http://maxcyte.com) and follow us on X and LinkedIn.

## NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>									
a)	Name	Maher Masoud								
<b>2</b>	<b>Reason for the notification</b>									
a)	Position/status	President, CEO and Director								
b)	Initial notification /Amendment	Initial notification								
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>									
a)	Name	MaxCyte Inc.								
b)	LEI	54930053YHXULRFCU991								
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>									
a)	Description of the financial instrument, type of instrument  Identification code	Common stock of 0.01 each  US57777K1060								
b)	Nature of the transaction	Grant of options and PSUs in respect of common stock								
c)	Price(s) and volume(s)	<p><u>Options:</u></p> <table border="1"> <tr> <td>Exercise Price(s)</td><td>Volume(s)</td></tr> <tr> <td>3.29</td><td>347,500</td></tr> </table> <p><u>PSUs:</u></p> <table border="1"> <tr> <td>Exercise Price(s)</td><td>Volume(s)</td></tr> <tr> <td>N/A</td><td>347,500</td></tr> </table>	Exercise Price(s)	Volume(s)	3.29	347,500	Exercise Price(s)	Volume(s)	N/A	347,500
Exercise Price(s)	Volume(s)									
3.29	347,500									
Exercise Price(s)	Volume(s)									
N/A	347,500									

d)	Aggregated information  - Aggregated volume  - Price	347,500 options and 347,500 PSUs (up to 781,875 shares of common stock if performance metrics for the PSUs are fully satisfied)  3.29 for the options; no exercise price for the PSUs
e)	Date of the transaction	14 March, 2025
f)	Place of the transaction	US Stock Exchange, Nasdaq

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>													
a)	Name	Douglas Swirsky												
<b>2</b>	<b>Reason for the notification</b>													
a)	Position/status	Chief Financial Officer												
b)	Initial notification /Amendment	Initial notification												
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>													
a)	Name	MaxCyte Inc.												
b)	LEI	54930053YHXULRFCU991												
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>													
a)	Description of the financial instrument, type of instrument  Identification code	Common stock of 0.01 each  US57777K1060												
b)	Nature of the transaction	Grant of options, RSUs and PSUs in respect of common stock												
c)	Price(s) and volume(s)	<u>Options:</u> <table border="1"> <tr> <td>Exercise Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>3.29</td> <td>150,000</td> </tr> </table> <u>RSUs:</u> <table border="1"> <tr> <td>Exercise Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>N/A</td> <td>37,500</td> </tr> </table> <u>PSUs:</u> <table border="1"> <tr> <td>Exercise Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>N/A</td> <td>37,500</td> </tr> </table>	Exercise Price(s)	Volume(s)	3.29	150,000	Exercise Price(s)	Volume(s)	N/A	37,500	Exercise Price(s)	Volume(s)	N/A	37,500
Exercise Price(s)	Volume(s)													
3.29	150,000													
Exercise Price(s)	Volume(s)													
N/A	37,500													
Exercise Price(s)	Volume(s)													
N/A	37,500													
d)	Aggregated information  - Aggregated volume	150,000 options, 37,500 RSUs and 37,500 PSUs (up to												

	- Price	234,375 shares of common stock if performance metrics for the PSUs are fully satisfied)  3.29 for the options; no exercise price for the RSUs and PSUs
e)	Date of the transaction	14 March, 2025
f)	Place of the transaction	US Stock Exchange, Nasdaq

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHUSRKRUVUOURR